Clinical Trial Update: The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for SIRIOX as first- or second-line chemotherapy in pancreatic ductal carcinoma; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• SIRIOX

Snippet

Sponsor: Fudan University | Conditions: Carcinoma, Pancreatic Ductal | Phase 2 | Status: UNKNOWN